Don P. Le

Array ( [id] => 17467689 [patent_doc_number] => 11274157 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => Constructs targeting histone H3 peptide/MHC complexes and uses thereof [patent_app_type] => utility [patent_app_number] => 16/477509 [patent_app_country] => US [patent_app_date] => 2018-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 3 [patent_no_of_words] => 91825 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 429 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16477509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072421 [patent_doc_number] => 20200190197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => IMMUNOTHERAPY USING ANTIBODIES THAT BIND PROGRAMMED DEATH LIGAND-1 (PD-L1) [patent_app_type] => utility [patent_app_number] => 16/472724 [patent_app_country] => US [patent_app_date] => 2017-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16472724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023499 [patent_doc_number] => 20190322754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => GHR-106 CHIMERIC ANTIGEN RECEPTOR CONSTRUCT AND METHODS OF MAKING AND USING SAME [patent_app_type] => utility [patent_app_number] => 16/474936 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16474936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650008 [patent_doc_number] => 10927171 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Antibody therapeutics that bind TIM3 [patent_app_type] => utility [patent_app_number] => 15/842161 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 30005 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15842161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556863 [patent_doc_number] => 20200062843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => ANTI-CD19 HUMANIZED ANTIBODY AND IMMUNE EFFECTOR CELL TARGETING CD19 [patent_app_type] => utility [patent_app_number] => 16/469091 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16469091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290665 [patent_doc_number] => 20190388468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => IMMUNE CELLS EXPRESSING AN ANTIGEN BINDING RECEPTOR AND A CHIMERIC COSTIMULATORY RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/465750 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 296 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790843 [patent_doc_number] => 20180155450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation [patent_app_type] => utility [patent_app_number] => 15/836810 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 312 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15836810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12238526 [patent_doc_number] => 20180071389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'Monoclonal Antibodies for Ebola and Marburg Viruses' [patent_app_type] => utility [patent_app_number] => 15/826537 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4221 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15826537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147863 [patent_doc_number] => 20190352409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/348319 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12159156 [patent_doc_number] => 20180030422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY' [patent_app_type] => utility [patent_app_number] => 15/783850 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17918 [patent_no_of_claims] => 80 [patent_no_of_ind_claims] => 77 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15783850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12621645 [patent_doc_number] => 20180099045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 15/782046 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15782046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300311 [patent_doc_number] => 20180201692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => ANTI-HER2 ANTIBODY VARIANTS [patent_app_type] => utility [patent_app_number] => 15/728816 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790774 [patent_doc_number] => 20180155427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => ANTIBODY MOLECULES TO PD-1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/727456 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15727456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061027 [patent_doc_number] => 10689445 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Anti-PD-L1 antibodies and diagnostic uses thereof [patent_app_type] => utility [patent_app_number] => 15/727388 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 34965 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15727388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205855 [patent_doc_number] => 20180051082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 (PD-1)' [patent_app_type] => utility [patent_app_number] => 15/726287 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 18629 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407184 [patent_doc_number] => 11248053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Method of modifying isoelectric point of antibody via amino acid substitution in CDR [patent_app_type] => utility [patent_app_number] => 15/725692 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 62 [patent_no_of_words] => 93009 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15725692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205856 [patent_doc_number] => 20180051081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'THERAPEUTIC CD47 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/723523 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 26258 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15723523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219234 [patent_doc_number] => 20180057592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'THERAPEUTIC CD47 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/723534 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23078 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15723534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360871 [patent_doc_number] => 20200016200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => MODULATING CYTOTOXIC CELL LYTIC GRANULE POSITIONING TO PROMOTE DIFFUSE KILLING IN CELLULAR THERAPIES [patent_app_type] => utility [patent_app_number] => 16/335565 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828707 [patent_doc_number] => 20200129635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => CYSTEINE MODIFIED ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 16/339719 [patent_app_country] => US [patent_app_date] => 2017-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339719 [rel_patent_id] =>[rel_patent_doc_number] =>)